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ABSTRACT 
In the present quality assurance research work Lamotrigine  Immediate Release tablet25mg  has been undertaken in accordance w ith Quality 
By Design guidelines. Quality by design a common understanding of the concept of ICH guideline Q8, Q9 & Q10 is now a day treaded as an 
essential tool in the process of formulation development. The development of Target Product Profile & Critical Quality Attributes were done 
after dew consideration of risk assessment before finalization of these attributes. As Lamotrigine is poorly soluble (BCS class-II) it may effect 
bioavailability, Hence, Solid dispersion approach was taken as risk assessment measure. Product design space & process parame ters were 
finalized on the basis of critical material attributes. Control strategies for continuous monitoring & updating of the process requirements were 
also highlighted. In the present research work critical process parameters were validated. The critical process parameter impacts on Quality. 
The Quality By Design principle & tools demonstrated in present research work will be useful in creating & developing control  strategies in 
similar formulation & process development.     
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INTRODUCTION 
The term convulsion refers to a transient alteration of 
behavior due to the disordered, synchronous & rhythmic 
firing of pupations of brain neurons. The term epilepsy 
refers to a disorder of brain function characterized by the 
periodic & unpredictable occurrence of seizures. 
The convulsions are common & frequently devastating 
disorders, affecting approximately 2.5 million people in the 
United States alone. Epileptic seizures often caused by 
transient impairment of consciousness, leaving the 
individual at risk of bodily harm and often interfering with 
education & employment. Lamotrigine is a phenyltriazine 
derivative initially developed as an antifolate  agent based 
upon the incorrect idea that reducing folate would 
effectively combact seizures. Structure activity studies 
indicate that its effectiveness as an anti seizure drug is 
unrelated to its antifolate properties. It was approved by the 
food & drug administration in  
1994. [1] The general principle of drug therapy of the 
epilepsies are summarize  below, lamotrigine is a 
anticonvulsant  agent. Lamotrigine suppresses tonic 
hindlimb &partial & secondarily generalized seizures. 
Lamotrigine blocks sustained repetitive firing of mouse 
spinal cord neurons & delays the recovery from inactivation 
of recombinant Na+ channels. This may well explain 
lamotrigines action on partial & secondarily generalized 
seizures.  Lamotrigine is effective against a broader 
spectrum of seizures, suggesting that lamotrigine may have 
actions in addition to regulating recovery from inactivation 
of Na+ channels. Patients who already taking a hepatic  
enzyme – including  antiseizure drugs should be given 
lamotrigine initially at 50 mg per day for 2 weeks. The dose 
is increased to 50 mg twice per day for 2 weeks & then 
increased in increments of  100 mg/day  each  week up to a 
maintenance dose of 300 to 500mg/day divided into two 
doses.
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MATERIAL AND METHODS 
Table 1: List of Materials Used 
S. N. Name of Materials Supplied By/Gifted By 
1 Lamotrigine   RA Chem Pharma Ltd (Hyd) as a gift sample 
2 Polyetrhylene glycol Research Lab Fine Chem Industry, Mumbai. 
3 Lactose Pallav chemical & solvent PVT. LTD. 
4 Magnesium stearate Highlab chemicals 
5 Sodium starch glycolate Research Lab Fine Chem Industry, Mumbai. 
6 Talc  Thermosil Fine Chem Industry 
7 Acetone  Research Lab Fine Chem Industry, Mumbai. 
 
Compression[2] 
Step 1- weighed  required  quantity of soli dispersion & pass 
through 40 mesh sieve. 
Step2-weight lactose pass through 40 mesh sieve.& put in to 
V blender. Check mesh size & intact mesh. 
Step3- Add lactose, sodium starch glycolate, talc, magnesium 
stearate & solid dispersion  in ascending order of blending. 
Step 4- Compress the tablet using a tablet compression 
machine. 
Table 2: Tablet Formula 
S. N. Ingredient  name  Analytical report Quantity  per tablet For 1000 tablet 
1 Solid dispersion equivalent to API 0.001 50mg 50gm 
2 Lactose  0.002 73mg 73gm 
3 Talc  0.003 15mg 15gm 
4 Sodium starch glycolate 0.004 7.5mg 7.5gm 
5 Magnesium stearate 0.005 4.5mg 4.5gm 
 
Evaluation and Result [3,4] 
Hardness:  
Tablet hardness is also known as tablet crushing strength & 
was determined by Monsanto hardness tester. It applies 
force to the tablet diametrically with the help of an in built 
spring. TrIP 2014()licate determinations were done. The 
hardness of the tablet is measured by using conventional 
hardness testers like Monsanto hardness tester. 
Thickness: 
The crown thickness of individual tablet from all the 
formulation was measured using screw gauge. 
Friability: 
Friability test is performed to assess the effect of abrasions 
and shock that may often cause tablet to chip, cap or break. 
Roche Friabilator was used for the purpose. For tablets with 
a unit weight equal to or less than 650 mg, take a sample of 
whole tablets corresponding as near as possible to 6.5 g. For 
tablets with a unit weight of more than 650 mg, take a 
sample of 10 whole tablets. The tablets should be carefully 
dedusted prior to testing. Accurately weigh the tablet 
sample, and place the tablets in the drum. Rotate the drum 
100 times, and remove the tablets. Remove any loose dust 
from the tablets as before, and accurately weigh. 
% F= (Wo – W / Wo) ×100 
Where, % F= Friability in percentage 
Wo= Initial weight of tablet 
W=   Final weight after revolution. 
Weight variation:  
Weigh individually 20 whole tablets, and calculate the 
average weight. The requirements are met if the weights of 
not more than 2 of the tablets differ from the average weight 
by more than the percentage listed in the accompanying 
table and no tablet differs in weight by more than double 
that percentage 
Drug content uniformity: 
The Lamotrigine content in tablets was determined by 
powdering 10 tablets in each batch. Powder equivalent to 
100 mg of Lamotrigine was dissolved in 0.1 N HCl. 1 ml of 
filtrate was further diluted to 100 ml with 0.1 N HCl and it 
was determined by spectroscopy at 340 nm. 
Disintegration time: 
The disintegration test was performed using Electrolab 
disintegrating apparatus. Six tablets were selected randomly 
from each batch for the disintegration test.Placed one tablet 
in each of the six tubes of the basketand operate the 
Disintegration apparatus using in simulated gastric fluid 
maintained at 37±0.5ºC. Disintegration time (DT) was 
measured for immediate release layer.  
 
Table No 3: Post Compression Study 
Hardness 
(kg/cm2) 
Thickness  Friability 
% 
Weight variation 
(mg) 
Drug content 
(%) 
Disintegration time 
(second) 
3.7 1.7 0.41 150.03 97.75 134 
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Dissolution study: 
In-vitro dissolution studies of floating tablets were carried 
out in USP dissolution test apparatus-II, employing a paddle 
type apparatus at 50 rpm using 900ml of 0.1N HCl as 
dissolution medium at 37±0.5ºC. One tablet was used in each 
test. At predetermined time intervals 5ml of the samples 
were withdrawn by means of a syringe. The volume 
withdrawn at each interval was replaced with same quantity 
of fresh dissolution medium maintained at 37±0.5ºC. The 
withdrawn samples were filtered through membrane filter 
0.45μm & analyzed by using UV spectrophotometer at λ max 
240 nm. This test was performed on 9 batches of immediate 
release tablets. 
Medium            : - 0.1N HCl  
Temperature   : - 37 ± 0.5ºC 
Volume             : - 900 ml.  
RPM                   : - 50 
Apparatus        : - Dissolution apparatus USP type II. 
Time           :- 30 mins 
Calibration Curve of Lamotrigine- 
 
Fig No.1 : Calibration Curve Of Lamotrigine 
Percentage Drug Release: 
 
Fig. No. 2 : Percentage drug release for Lamotrigine 
immediate release tablet 
Stability Testing [5] 
For long term studies, frequency of testing should be 
sufficient to establish the stability profile of the drug 
substance. At the accelerated storage condition, a minimum 
of three time points, including the initial and final time point 
(e. g 0, 3 and 6 months), from a 6- month study was 
recommended. When testing at the intermediate storage 
condition is called for as a result of significant change at the 
accelerated storage. 
 
Table 4: Result of Stability Testing 
 
Parameters 
Initial 
Temp :400 c±20 c 
Humidity :75 ± 5% RH 
After 1 month After 2 month After 3 month 
Temp :400 c±20 c 
Humidity :75 ± 5% RH 
Hardness(3 to 5 kg/cm2)  3.7 3.72 3.75 3.78 
Disintegration time(sec)NMT 3 min 134 134 135 138 
Drug content (90 to 101%) 95.75 95.75 94.87 94.23 
Appearance   White tablet White tablet White tablet White tablet 
 
The product meets the stability requirement for 6 month as per ICH guideline. 
CONCLUSION 
The present research work highlighted all the activities 
involved to built quality into the product using quality by 
design techniques research work. All the steps such as 
identification of target product profile , critical quality 
attributes, product design space, process design space, risk 
assessment & product characterization were conducted 
systematically. Additionally critical quality attributes& 
control strategy & process validation were also carried out. 
The stability data shows the product is stable at 400c ± 20c 
for 3 months at 75 ± 5% RH . The experimentation were 
planed as per plan of work & all the recommended 
parameters of quality by design requirement as per ICH Q2 
(R1) guidelines were followed step wise. This research work 
highlights that there are many strategic control points which 
are required to be addressed systematically to achieve 
quality assurance requirements in the manufacturing & 
control of pharmaceutical formulations to ensure that the 
quality is built in to the product. 
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